1 / 1

TIMIC

TIMIC. Majority in IS therapy arm showed an ↑ in LVEF (26.54-45.6%) and ↓ in LVEDD (68.4-54.4 mm) No patients in placebo arm improved; some showed further ↓ in LVEF and ↑ in LVEDD No CV death or transplant at 6 months in both arms. (p < 0.001).

zilya
Download Presentation

TIMIC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TIMIC Majority in IS therapy arm showed an ↑ in LVEF (26.54-45.6%) and ↓ in LVEDD (68.4-54.4 mm) No patients in placebo arm improved; some showed further ↓ in LVEF and ↑ in LVEDD No CV death or transplant at 6 months in both arms (p < 0.001) Trial design: Patients with virus-negative inflammatory cardiomyopathy were randomized to either immunosuppressive (IS) therapy with prednisone and azathioprine or placebo for 6 months. Echocardiographic parameters were compared at 6 months. Results 30 19.1 15 -6.4 Conclusions % 0 • IS therapy in virus-negative inflammatory cardiomyopathy may be associated with an improvement in LVEF and LVEDD, compared with placebo • Further corroboration is necessary • May represent novel approach to HF management in these patients -15 Change in LVEF from baseline IS therapy (n = 43) Placebo (n = 42) Frustaci A, et al. Eur Heart J 2009;Jun 25:[Epub]

More Related